Jupiter Asset Management Ltd. increased its position in Danaher Corporation (NYSE:DHR – Free Report) by 19.5% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 267,167 shares of the conglomerate’s stock after purchasing an additional 43,540 shares during the quarter. Jupiter Asset Management Ltd.’s holdings in Danaher were worth $52,776,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also added to or reduced their stakes in DHR. Red Tortoise LLC raised its holdings in Danaher by 175.0% in the second quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock worth $30,000 after buying an additional 98 shares during the last quarter. Ramirez Asset Management Inc. purchased a new stake in Danaher during the second quarter valued at $40,000. Costello Asset Management INC purchased a new stake in shares of Danaher during the 1st quarter valued at about $41,000. Mowery & Schoenfeld Wealth Management LLC grew its position in Danaher by 53.8% during the first quarter. Mowery & Schoenfeld Wealth Management LLC now owns 203 shares of the conglomerate’s stock valued at $42,000 after buying an additional 71 shares during the period. Finally, Strengthening Families & Communities LLC raised its holdings in Danaher by 81.4% in the 1st quarter. Strengthening Families & Communities LLC now owns 254 shares of the conglomerate’s stock worth $52,000 after purchasing an additional 114 shares during the period. Institutional investors own 79.05% of the company’s stock.
Insider Buying and Selling
In other Danaher news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director owned 20,751 shares of the company’s stock, valued at $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 11.10% of the company’s stock.
Analyst Ratings Changes
View Our Latest Stock Analysis on Danaher
Danaher Price Performance
Shares of DHR opened at $215.80 on Wednesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $258.23. The business’s 50-day moving average is $204.36 and its two-hundred day moving average is $200.64. The company has a market capitalization of $152.43 billion, a P/E ratio of 44.49, a P/E/G ratio of 3.28 and a beta of 0.81.
Danaher (NYSE:DHR – Get Free Report) last posted its earnings results on Tuesday, October 21st. The conglomerate reported $1.89 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $6 billion. During the same period last year, the firm earned $1.71 EPS. The company’s quarterly revenue was up 4.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Research analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.
Danaher Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Friday, September 26th were given a $0.32 dividend. The ex-dividend date was Friday, September 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. Danaher’s dividend payout ratio (DPR) is 26.39%.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read More
- Five stocks we like better than Danaher
- Why Are Stock Sectors Important to Successful Investing?
- Amazon Is One of the Clearest Buys If the Market Dips Again
- Investing in Commodities: What Are They? How to Invest in Them
- CoreWeave’s Guidance Cut: A Buying Opportunity in Disguise?
- How to Use the MarketBeat Dividend Calculator
- Strategy Shares Plunge as Bitcoin Retreats—More Pain Ahead?
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
